SSY Group gains third NMPA approval for Upadacitinib bulk drug

Bulletin Express03-31

SSY Group Limited announced on 31 March 2026 that the National Medical Products Administration of China has approved the registration of the Group’s Upadacitinib active pharmaceutical ingredient for commercial use in downstream preparations.

The latest clearance marks the third Upadacitinib registration approval granted to entities in mainland China, positioning SSY Group among a limited cohort of domestic suppliers of the JAK-1 inhibitor.

Upadacitinib is indicated for autoimmune conditions including rheumatoid arthritis, Crohn's disease, atopic dermatitis, psoriatic arthritis, ulcerative colitis and giant cell arteritis, expanding the Group’s immunology portfolio.

The filing was issued as a voluntary announcement to update shareholders and potential investors on product development progress; the company did not disclose financial metrics related to the approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134616163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 08:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134616163","market":"us","top_or_hot":-1,"title":"SSY Group gains third NMPA approval for Upadacitinib bulk drug","media":"Bulletin Express","content":"<p>SSY Group Limited announced on 31 March 2026 that the National Medical Products Administration of China has approved the registration of the Group’s Upadacitinib active pharmaceutical ingredient for commercial use in downstream preparations.</p>\n<p>The latest clearance marks the third Upadacitinib registration approval granted to entities in mainland China, positioning SSY Group among a limited cohort of domestic suppliers of the JAK-1 inhibitor.</p>\n<p>Upadacitinib is indicated for autoimmune conditions including rheumatoid arthritis, Crohn's disease, atopic dermatitis, psoriatic arthritis, ulcerative colitis and giant cell arteritis, expanding the Group’s immunology portfolio.</p>\n<p>The filing was issued as a voluntary announcement to update shareholders and potential investors on product development progress; the company did not disclose financial metrics related to the approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group gains third NMPA approval for Upadacitinib bulk drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group gains third NMPA approval for Upadacitinib bulk drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-31 08:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY Group Limited announced on 31 March 2026 that the National Medical Products Administration of China has approved the registration of the Group’s Upadacitinib active pharmaceutical ingredient for commercial use in downstream preparations.</p>\n<p>The latest clearance marks the third Upadacitinib registration approval granted to entities in mainland China, positioning SSY Group among a limited cohort of domestic suppliers of the JAK-1 inhibitor.</p>\n<p>Upadacitinib is indicated for autoimmune conditions including rheumatoid arthritis, Crohn's disease, atopic dermatitis, psoriatic arthritis, ulcerative colitis and giant cell arteritis, expanding the Group’s immunology portfolio.</p>\n<p>The filing was issued as a voluntary announcement to update shareholders and potential investors on product development progress; the company did not disclose financial metrics related to the approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"","article_id":"1134616163","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134616163","pubTimestamp":1774916597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"SSY Group Limited announced on 31 March 2026 that the National Medical Products Administration of China has approved the registration of the Group’s Upadacitinib active pharmaceutical ingredient for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02005":"石四药集团"},"translate_title":"SSY集团Upadacitinib原料药获得第三个NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY Group Limited announced on 31 March 2026 that the National Medical Products Administration of China has approved the registration of the Group’s Upadacitinib active pharmaceutical ingredient for commercial use in downstream preparations.\nThe latest clearance marks the third Upadacitinib registration approval granted to entities in mainland China, positioning SSY Group among a limited cohort of domestic suppliers of the JAK-1 inhibitor.\nUpadacitinib is indicated for autoimmune conditions including rheumatoid arthritis, Crohn's disease, atopic dermatitis, psoriatic arthritis, ulcerative colitis and giant cell arteritis, expanding the Group’s immunology portfolio.\nThe filing was issued as a voluntary announcement to update shareholders and potential investors on product development progress; the company did not disclose financial metrics related to the approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134616163","isCrawlerRequest":true}